Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of intra-articular RTX-GRT7039 for knee osteoarthritis pain
jRCT2031220354Phase 3Completed
- Sponsor
- Grünenthal GmbH
- Start
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in knee osteoarthritis (OA) comparing RTX-GRT7039 with Placebo (2 arms). Primary endpoint: Change in WOMAC pain subscale score in the index knee. Started Dec 2022; status: completed.
02
Drugs
RTX-GRT7039
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on jRCT2031220354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220354.